Previous findings by our laboratory29 have highlighted that in other subtypes, including ER+ breast cancer, loss of type I IFN regulators can occur post tumor dissemination to bone, reducing the impact of IRF7 and IRF9 as primary tumor prognostic markers in ER +ve disease. This evidence concerns the gene IRF7 and neoplasm.